Ozempic Patient resources tirzepatide surmount 5 SURMOUNT 1 (NEJM 2022) tested tirzepatide a dual GIP GLP 1 receptor agonist in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants We have had great success in helping patients get to a healthier goal weight with both Semaglutide and Tirzepatide weekly injections. Are you needing to lose those 15 20 pounds+ and don't know Ozempic Rebound: You will regain 66% of your weight loss if you don't have an exit strategy!